Comparative Pharmacology
Head-to-head clinical analysis: LIPIDIL versus TRIGLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPIDIL versus TRIGLIDE.
LIPIDIL vs TRIGLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIPIDIL (fenofibrate) is a fibric acid derivative that activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), leading to increased lipolysis and clearance of triglyceride-rich particles, and increased synthesis of apolipoproteins A-I and A-II.
TRIGLIDE (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) activator. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
130 mg orally once daily.
Initial dose: 60 mg (1 tablet) twice daily, gradually increased over 3-7 days to maintenance dose of 120 mg twice daily.
None Documented
None Documented
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This supports once-daily dosing; steady-state is achieved after ~5 days.
22-35 hours; prolonged in renal impairment (up to 50 hours).
Primarily renal excretion of glucuronide conjugates; approximately 70% of a single oral dose is recovered in urine (mostly as fenofibric acid glucuronide), and about 6% is excreted in feces.
Primarily renal (70% as unchanged drug), 20% fecal, <10% biliary.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic